Unani Medicine Recall Readiness: A Scientific Review for Healthcare Professionals

Abstract

Unani medicine, a traditional system rooted in Greco-Arabic medical knowledge, continues to be utilized globally. However, the increasing integration of Unani products into mainstream health care, coupled with regulatory scrutiny, highlights the importance of robust recall readiness. This review systematically evaluates the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, emerging therapies, and guideline recommendations related to Unani medicine recalls. The aim is to provide clinicians and healthcare professionals with actionable insights to ensure patient safety and regulatory compliance in the context of Unani medicine use and recalls.

Introduction

Unani medicine, also known as Greco-Arabic medicine, is an ancient holistic medical system that has persisted for centuries, especially in South Asia, the Middle East, and parts of Europe. As Unani formulations gain popularity and are increasingly commercialized, concerns about quality control, safety, and potential adverse events have come to the forefront. Recall readiness—defined as the capacity to rapidly identify, communicate, and remove potentially harmful or non-compliant products from the market—is a critical aspect of patient safety and regulatory oversight. This review addresses the scientific, clinical, and regulatory dimensions of Unani medicine recall readiness, synthesizing current evidence and offering practical implications for healthcare professionals.

Epidemiology / Disease Burden

The global use of Unani medicine is significant, with millions relying on Unani formulations for a variety of acute and chronic health conditions. In India alone, the Unani medicinal market is valued at several billion US dollars, reflecting widespread utilization. However, sporadic reports of adverse drug reactions (ADRs), product adulteration, contamination, and mislabeling have raised public health concerns. According to recent pharmacovigilance data, the incidence of documented adverse events associated with Unani medicines remains underreported due to limited surveillance infrastructure. Nonetheless, regulatory authorities in countries such as India, Pakistan, and the United Arab Emirates have periodically issued recalls of Unani products for reasons ranging from microbial contamination to undisclosed pharmaceutical ingredients. These recalls underscore the necessity for heightened recall preparedness within the Unani industry and among healthcare providers.

Pathophysiology

Adverse outcomes prompting Unani medicine recalls may arise from multiple pathophysiological mechanisms. Contamination with heavy metals (e.g., lead, arsenic, mercury) can cause systemic toxicity, leading to nephrotoxicity, hepatotoxicity, or neurotoxicity. Microbial contamination, particularly by pathogenic bacteria or fungi, may result in infectious complications. The presence of undeclared synthetic drugs (such as corticosteroids or nonsteroidal anti-inflammatory drugs) can trigger allergic reactions, metabolic disturbances, or drug interactions. Additionally, inappropriate formulation or dosing errors may cause idiosyncratic or dose-dependent toxicity. Understanding these mechanisms is fundamental for clinicians to anticipate, recognize, and manage complications associated with recalled Unani products.

Risk Factors

Several risk factors predispose to adverse events and subsequent recalls in Unani medicine. These include inadequate quality control during manufacturing, lack of standardization of raw materials, insufficient labeling, and poor pharmacovigilance systems. Patients at higher risk include those with pre-existing hepatic or renal dysfunction, pregnant or breastfeeding women, pediatric and geriatric populations, and individuals with polypharmacy. Additionally, products sourced from unregulated markets or prepared by unlicensed practitioners carry a significantly higher risk of adulteration or contamination.

Clinical Features

The clinical manifestations of adverse events leading to Unani medicine recalls are diverse and may mimic other medical conditions. Presentations may include acute gastrointestinal symptoms (nausea, vomiting, diarrhea), cutaneous allergic reactions, hepatic dysfunction (jaundice, elevated transaminases), nephrotoxicity (oliguria, elevated creatinine), neurotoxicity (encephalopathy, peripheral neuropathy), or systemic infections. In cases of adulteration with pharmaceuticals, patients may present with unexplained steroid toxicity, hypoglycemia, hypertension, or other drug-specific side effects. Timely recognition of these features is essential for effective clinical management and regulatory reporting.

Diagnosis

Diagnosis of adverse events related to Unani medicine involves a high index of suspicion, a detailed patient history including use of traditional medicines, and targeted laboratory investigations. Analytical testing of suspected products for heavy metals, microbial contamination, and pharmaceutical adulterants is crucial. Blood and urine toxicology screens, liver and kidney function tests, and imaging studies may aid in assessing organ involvement. Collaboration with pharmacovigilance centers and regulatory agencies enhances the ability to identify emerging patterns and facilitate timely recalls.

Treatment & Management

Management of adverse events from recalled Unani medicines is primarily supportive and symptom-driven. In cases of heavy metal toxicity, chelation therapy may be indicated. Infectious complications require appropriate antimicrobial therapy, while drug-induced organ dysfunction may necessitate withdrawal of the offending agent and supportive care. Patient education on the importance of reporting side effects and avoiding unregulated products is vital. In severe cases, hospitalization and multidisciplinary management may be required. Prompt notification of regulatory bodies enables widespread risk mitigation and facilitates coordinated recall actions.

Recent Advances / Emerging Therapies

Recent advances in recall readiness for Unani medicine include the implementation of advanced analytical techniques, such as inductively coupled plasma mass spectrometry (ICP-MS) for heavy metal detection, and high-performance liquid chromatography (HPLC) for pharmaceutical adulterants. Digital pharmacovigilance platforms and barcoding systems enhance traceability and rapid response to safety signals. The integration of artificial intelligence in signal detection and recall logistics is an emerging area with significant promise. Furthermore, international harmonization of quality standards, such as those advocated by the World Health Organization (WHO), is gradually improving product safety and recall efficacy within the Unani sector.

Guideline Recommendations

Leading regulatory agencies and professional bodies recommend stringent quality assurance protocols for Unani medicine manufacturers, including Good Manufacturing Practices (GMP), batch-wise testing for contaminants, and transparent labeling. Healthcare professionals are advised to maintain vigilance regarding potential adverse events, encourage patient disclosure of traditional medicine use, and promptly report suspected cases to appropriate authorities. Patient education initiatives and continuing medical education (CME) on traditional medicine safety are endorsed to enhance recall readiness. The development and adherence to national and international recall guidelines are essential for safeguarding public health.

Conclusion

Recall readiness in Unani medicine is a critical facet of patient safety and public health protection. Clinicians and healthcare professionals must possess an in-depth understanding of the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and management strategies related to Unani medicine recalls. Recent technological and regulatory advances offer promising avenues for improving recall efficiency and minimizing adverse outcomes. Ongoing vigilance, interdisciplinary collaboration, and adherence to evidence-based guidelines are imperative for optimizing the safe integration of Unani medicine into contemporary healthcare systems.